{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:11Z","timestamp":1793812391396,"version":"4.6.1"},"reference-count":26,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,3,20]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Follicular dendritic cell sarcoma (FDCS) is a rare and unusual cancer that arises from sustentacular cells of the lymph node that present antigen to B cells, rather than lymphocytes themselves. While surgery for primary disease is still paramount in primary management, for unresectable, recurrent and metastatic tumours, FDCS is frequently treated with anthracycline-based lymphoma chemotherapy regimens. In recent years, it is clear that Programmed Cell Death 1 (PD1)-directed immune checkpoint inhibitors (ICIs) are active in Hodgkin lymphoma, but significantly less active in non-Hodgkin\u2019s lymphoma. These data raised the question of whether FDCS respond to ICI therapy. We present two patients with FDCS who were treated with nivolumab and ipilimumab with evidence of tumour response. These cases also highlight the difficulty in arriving at a proper diagnosis, emphasising the need for expert review of pathology to optimise treatment for these and other patients with sarcoma.<\/jats:p>","DOI":"10.1136\/bcr-2020-234363","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T06:15:26Z","timestamp":1587622526000},"page":"e234363","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab"],"prefix":"10.1136","volume":"13","author":[{"given":"Mee-young","family":"Lee","sequence":"first","affiliation":[{"name":"Monter Cancer Center, Northwell Health, Lake Success, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Bernabe-Ramirez","sequence":"additional","affiliation":[{"name":"Medical Oncology, Essen Medical, Long Island City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Pathology, Northwell Health, Great Neck, New York, USA"},{"name":"Pathology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-2528","authenticated-orcid":false,"given":"Robert G","family":"Maki","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"2025082709285804000_13.4.e234363.1","first-page":"562","article-title":"A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases","volume":"122","author":"Monda","year":"1986","journal-title":"Am J Pathol"},{"key":"2025082709285804000_13.4.e234363.2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31824be22b"},{"key":"2025082709285804000_13.4.e234363.3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/PAS.0000000000000170","article-title":"Inflammatory pseudotumor-like follicular dendritic cell tumor of liver and spleen: granulomatous and eosinophil-rich variants mimicking inflammatory or infective lesions","volume":"38","author":"Li","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"2025082709285804000_13.4.e234363.4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181705"},{"key":"2025082709285804000_13.4.e234363.5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132409"},{"key":"2025082709285804000_13.4.e234363.6","first-page":"144","article-title":"Follicular dendritic cell tumor: review of the entity","volume":"15","author":"Perez-Ordo\u00f1ez","year":"1998","journal-title":"Semin Diagn Pathol"},{"key":"2025082709285804000_13.4.e234363.7","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199608000-00003"},{"key":"2025082709285804000_13.4.e234363.8","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ejca.2015.06.109","article-title":"Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas","volume":"51","author":"Gounder","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025082709285804000_13.4.e234363.9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/annonc\/mdy032","article-title":"Next-generation immunotherapies for lymphoma: one foot in the future","volume":"29","author":"Manson","year":"2018","journal-title":"Ann Oncol"},{"key":"2025082709285804000_13.4.e234363.10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000481800","article-title":"Checkpoint Inhibition in Hodgkin Lymphoma - a Review","volume":"40","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Oncol Res Treat"},{"key":"2025082709285804000_13.4.e234363.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"2025082709285804000_13.4.e234363.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"2025082709285804000_13.4.e234363.13","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025082709285804000_13.4.e234363.14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000590"},{"key":"2025082709285804000_13.4.e234363.15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anndiagpath.2016.05.003","article-title":"Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1","volume":"23","author":"Agaimy","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"2025082709285804000_13.4.e234363.16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27491","article-title":"Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma","volume":"66","author":"Bose","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2025082709285804000_13.4.e234363.17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-218889","article-title":"Follicular dendritic sarcoma masquerading as fibrosing mediastinitis","volume":"2017","author":"Cingam","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2025082709285804000_13.4.e234363.18","doi-asserted-by":"crossref","first-page":"16463","DOI":"10.18632\/oncotarget.14864","article-title":"Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing","volume":"8","author":"Lorenzi","year":"2017","journal-title":"Oncotarget"},{"key":"2025082709285804000_13.4.e234363.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9508"},{"key":"2025082709285804000_13.4.e234363.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.1950"},{"key":"2025082709285804000_13.4.e234363.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309"},{"key":"2025082709285804000_13.4.e234363.22","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025082709285804000_13.4.e234363.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3411"},{"key":"2025082709285804000_13.4.e234363.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3049"},{"key":"2025082709285804000_13.4.e234363.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905301116"},{"key":"2025082709285804000_13.4.e234363.26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00830","article-title":"Tertiary lymphoid structures: an anti-tumor school for adaptive immune cells and an antibody factory to fight cancer?","volume":"8","author":"Teillaud","year":"2017","journal-title":"Front Immunol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-234363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:29:03Z","timestamp":1756312143000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-234363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,22]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bcr-2020-234363"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-234363","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}